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Inflammation in de-endothelialised arteries contributes to the development of cardiovascular diseases.
The process that initiates this inflammatory response is the adhesion of monocytes/macrophages to
exposed vascular smooth muscle cells, typically stimulated by cytokines such as tumour necrosis
factor-a (TNF). The aim of this study was to determine the effect of the sphingolipid sphingosylphospho-
rylcholine (SPC) on the interaction of monocytes/macrophages with vascular smooth muscle cells. Rat
aortic smooth muscle cells and rat bone marrow-derived macrophages were co-cultured using an
in vitro assay following incubation with sphingolipids to assess inter-cellular adhesion. We reveal that
SPC inhibits the TNF-induced adhesion of macrophages to smooth muscle cells. This anti-adhesive effect
was the result of SPC-induced changes to the smooth muscle cells (but not the macrophages) and was
mediated, at least partly, via the sphingosine 1-phosphate receptor subtype 2. Lipid raft domains were
also required. Although SPC did not alter expression or membrane distribution of the adhesion proteins
intercellular adhesion molecule-1 and vascular cellular adhesion protein-1 in smooth muscle cells, SPC
preincubation inhibited the TNF-induced increase in inducible nitric oxide synthase (NOS2) resulting
in a subsequent decrease in nitric oxide production. Inhibiting NOS2 activation in smooth muscle cells
led to a decrease in the adhesion of macrophages to smooth muscle cells. This study has therefore delin-
eated a novel pathway which can inhibit the interaction between macrophages and vascular smooth
muscle cells via SPC-induced repression of NOS2 expression. This mechanism could represent a potential
drug target in vascular disease.
 2016 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Mononuclear cell adhesion to endothelial cells and their subse-
quent infiltration into the vascular wall is an important initiating
event in the development of atherosclerosis and in blood vessel
re-occlusion (restenosis) following angioplasty [1,2]. Adhesion is
typically stimulated by cytokines such as tumour necrosis factor-
a (TNF) released from inflammatory cells and vascular smooth
muscle cells (SMC) [3]. These cytokines lead to an upregulation
of adhesion proteins in endothelial cells, in particular vascular cell
adhesion molecule-1 (VCAM-1) and intercellular adhesion
molecule-1 (ICAM-1), which facilitate monocyte adhesion [4]. Fol-
lowing adhesion to endothelial cells, tissue infiltration of mono-
cytes and their subsequent differentiation to macrophages lead
to a local inflammatory response which drives the development
of vascular disease [5]. This consists of changes in the vascular
SMC phenotype from a quiescent to a more proliferative andmigratory cell type [6]. While research has focussed on the mech-
anisms of monocyte/macrophage adhesion to endothelial cells, rel-
atively little attention has been paid to interaction of
monocyte/macrophage with vascular SMC. Evidence now indicates
that monocyte/macrophage adhesion to vascular SMC is likely to
be involved in the initiation of vascular disease [7,8]. It is clear that
macrophages and vascular SMC are in direct contact in atheroscle-
rotic plaque regions of human blood vessels [9]. In addition, prolif-
erating neointimal vascular SMC, resulting from vascular injury
and endothelial denudation, display an increased binding of mono-
cytes [10]. This evidence demonstrates that monocytes/-
macrophages can not only adhere to vascular SMC, but that this
interaction may also be an integral part of vascular disease
pathogenesis.
Sphingolipids are a class of lipid mediators which are naturally
occurring in blood and may regulate cell–cell interactions [11]. The
most studied sphingolipid, sphingosine 1-phosphate (S1P) is stored
in erythrocytes and is an important component of lipoproteins
[12,13]. S1P actions are mediated by a specific class of G-protein-
coupled 7-transmembrane receptors consisting of 5 isoforms,
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signalling pathways such as intracellular calcium release and acti-
vation of mitogen-activated protein kinases. Most cell types,
including vascular SMC, express at least 2 isoforms of the S1P
receptor [15,16]. Recent evidence now suggests that another sph-
ingolipid, sphingosylphosphorylcholine (SPC), can also have
important effects on the cardiovascular system [17]. SPC, similar
to S1P, is naturally occurring. The source(s) of SPC production,
release and metabolism in vivo are not clear although the SPC con-
centration is raised in serum compared to plasma suggesting
release from platelets and SPC (similar to S1P) is also a constituent
of lipoproteins [18,19]. Although a high affinity receptor for SPC
has not been identified, SPC can act as a low affinity agonist at
S1P receptors [20]. In addition, recent evidence has indicated that
SPC signal transduction to intracellular pathways can also occur via
lipid raft membrane domains [21,22]. These lipid raft-dependent
effects have been observed in several cell types including vascular
smooth muscle and could potentially be receptor-independent
[23]. Such effects could involve direct interaction of SPC with these
membrane lipid domains. In vascular SMC, we and others have
shown that SPC has several actions including vasoconstriction
and proliferation [24,25] although whether these are receptor-
dependent or receptor-independent is not known. The effects of
SPC on monocyte/macrophage adhesion to vascular SMC have
not previously been investigated.
In the current study we have investigated the effect of SPC on
macrophage adhesion to vascular SMC using an in vitro co-
culture system. SPC significantly decreased the adhesion of rat
bone marrow-derived macrophages (BMDM) to rat aortic vascular
SMC following stimulation with TNF. This effect was lipid raft-
dependent and occurred via an inhibition of NOS2 expression.2. Methods
2.1. Preparation of primary cultured cells
Rat BMDM and rat aortic SMC were prepared as previously
described [26,27]. Sprague–Dawley male rats (6 weeks old, 300–
350 g) were maintained in accordance with institutional guidelines
and were euthanised by approved schedule 1 methods. Bone
marrow was extracted from male Sprague–Dawley rats. Rat
bone-marrow-derived macrophages (BMDMs) were isolated by
aspiration of the femur and tibia and suspended in culture medium
comprising Dulbecco’s modified Eagle’s medium supplemented
with 10% heat inactivated foetal calf serum, 100 U/ml penicillin
and 100 lg/ml streptomycin with the addition of 20% L929-
conditioned medium produced using a standard protocol [27]. This
yields a population of >95% macrophages after 7 days of culture.
Cells were detached by scraping into culture medium or phosphate
buffered saline (PBS).
Primary rat aortic SMC were prepared and maintained as previ-
ously described [26]. For experimental use cells were grown to 70–
90% confluence and placed in serum free DMEM for 24 h before
treatment. Primary SMC were used at passage numbers 3–8.2.2. Cell adhesion assay
Rat BMDM were harvested by scraping and washed in PBS.
BMDM were labelled by incubating with 1.5 lM calcein ace-
toxymethylester (AM) for 30 min at 37 C, centrifuged at
1200 rpm for 4 min and the pellet resuspended in DMEM. BMDM
were labelled with calcein AM directly before co-culture. Rat aortic
SMC were grown to confluence in 24-well plates. All preincuba-
tions of SMC and BMDM were performed separately immediately
before co-culture. Rat aortic SMC were washed once with PBSbefore labelled BMDM were added at a concentration of
5  106 ml1. Cells were co-cultured at 37 C for 15 min. Unbound
BMDM were aspirated and wells washed 3 times to remove non-
adherent cells. Cells were fixed for 10–15 min at room temperature
in 3% paraformaldehyde diluted in PBS. Wells were imaged to mea-
sure adherent fluorescent BMDM using a stereo microscope fitted
with a super high pressure mercury lamp (SMZ1500; Nikon, Sur-
rey, UK) with excitation and emission wavelengths at 494 nm
and 517 nm, respectively. Analysis of the acquired fluorescence
images was completed using ImageJ software. Results were
expressed as a fold increase compared to control (untreated)
samples.
2.3. Cell protein extraction and immunoblotting
Cells were incubated with sphingolipids and pharmacological
reagents as described [15]. At the end of the incubation period
the culture dishes were placed on ice. Culture medium was dis-
carded and cells were rinsed in Tris-buffered saline and scraped
into extraction buffer containing 1% Nonidet P-40, 0.5% sodium
deoxycholate and 0.1% SDS in Tris-buffered saline, 0.1 mM phenyl-
methylsulphonyl fluoride and 1 lg/ml pepstatin A. Cell lysates
were centrifuged at 14,000 rpm and 4 C for 10 min. Following
measurement of the protein content using a Lowry assay, super-
natants were mixed with SDS sample buffer, containing 50 mM
Tris–HCl (pH 6.8), 2% SDS, 6% glycerol, 100 mM DL-Dithiothreitol
and bromophenol blue. Samples were then boiled for 5 min, cooled
on ice and stored at 20 C until use. For immunoblotting samples
were separated by SDS–PAGE and transferred onto nitrocellulose
membrane as previously described [26]. These membranes were
incubated in primary antibodies which were then followed by
detection with HRP-conjugated secondary antibodies and the
immunoreactive bands were visualised by enhanced chemilumi-
nescence as previously described [15]. Bands on immunoblots
were quantified by densitometry using Biorad Multianalyst
software.
2.4. Nitrate measurement
The reaction product of nitric oxide (NO), nitrate, was detected
using a Griess-based colorimetric assay (Cayman, Ann Arbor, MI,
USA). The assay was performed in a 96 well-plate according to
the manufacturer’s instructions. Standard dilutions were prepared
in duplicate. Conditioned medium from treated rat aortic SMC was
loaded in duplicate to triplicate. The colour was allowed to develop
for 10 min before measurement of the absorbance at 540 nm
wavelength using a microplate reader (Labsystems Multiskan MS,
Franklin, MA, USA). Based on the readings of the standard dilutions,
a linear standard curve was created and the nitrate concentration
in the samples was calculated accordingly.
2.5. Preparation of lipid raft fractions
Triton X-100-resistant lipid rafts were prepared previously pub-
lished [28]. In brief, vascular SMC (2  107) were washed with ice-
cold PBS and suspended in 1 ml of 2-(morpholino)ethanesulphonic
acid (MES)-buffered saline (25 mM MES, pH 6.5, 150 mM NaCl),
containing 1% Triton X-100, 10 lg/ml benzamidine, 1 lg/ml leu-
peptin, 1 lg/ml pepstatin A, 5 mM NaVO4, 10 mM NaF and 1 mM
PMSF and incubated on ice for 30 min. Extracts were subjected to
10 strokes of a Dounce homogeniser and adjusted to 40% sucrose
in MES-buffered saline. Cell extracts in 40% sucrose, were overlaid
with 7.0 ml 35% sucrose and 3.0 ml 5% sucrose in MES-buffered sal-
ine and centrifuged at 175,000g (Beckman SW41 rotor) for 21 h,
4 C. Nine fractions (1 ml) were collected from the top of the
gradient.
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Lyophilised SPC was dissolved in methanol to create stock con-
centrations of 10 mM SPC. Aliquots of 50 ll were prepared and
stored at 20 C. Before use aliquots were heated at 37 C for
20 min with brief vortexing every 5 min. The methanol was evap-
orated with nitrogen gas. Sphingolipids were dissolved in sterile
3.6 mg/ml BSA solution containing 10% DMSO in distilled water.
To ensure SPC was dissolved fully, reconstituted aliquots were vor-
texed for 1 min, followed by heating at 37 C for 15 min. A concen-
tration of 10 lM SPC was used unless otherwise indicated. These
concentrations achieve maximal or close to maximal effects in con-
centration–effect curves as assessed previously [24].2.7. Analyses and statistics
Each ‘n’ number represents a separate primary culture (i.e. a dif-
ferent rat) for both aortic SMC and BMDM. Statistical significance
was determined by an unpaired Students’ t-test for comparisons
between two groups, or analysis of variance followed by a Bonfer-
roni post hoc test for comparisons between more than two groups.
A value of p < 0.05 was considered significant.2.8. Materials
Sphingolipids including S1P, SPC and 1400W were purchased
from Cayman, Ann Arbor, MI, USA. JTE-013 and VPC-23019 were
from Tocris, Bristol, UK. Calcein AM was purchased from ANASPEC,
Fremont, CA, USA. Antibodies against NOS2, ICAM-1, VCAM-1 and
GAPDHwere from Santa Cruz Biotechnology, Heidelberg, Germany.
Antibodies against IjB-a and phospho-IKKa/b were from Cell Sig-
naling Technology, Danvers, MA, USA. All tissue culture reagents
were purchased form Life Technologies, Paisley, UK. All other
reagents were purchased from Sigma-Aldrich Company Ltd, Dorset,
UK.3. Results
3.1. SPC inhibits TNF-induced macrophage adhesion to SMC
To assess macrophage adhesion to vascular SMC, we used a
co-culture model consisting of a 15 min incubation of primary
cultured rat aortic SMC and rat BMDM. In order to produce a
pro-inflammatory environment similar to that observed in vivo,
we incubated both cell types separately for 24 h with 10 ng/ml
TNF before the co-culture incubation. This induced a significant
increase in BMDM adhesion to SMC by approximately 3-fold com-
pared to unstimulated cells (Fig. 1A). To initially examine the
effects of SPC on BMDM adhesion, both BMDM and SMC were incu-
bated separately with 1 lM or 10 lM SPC for 24 h in the presence
of TNF (Fig. 1A). The number of adherent cells following co-culture
was unchanged in cells incubated with 1 lM SPC compared to
vehicle-treated cells. In contrast, 10 lM SPC preincubation signifi-
cantly inhibited TNF-induced BMDM adhesion to SMC. SPC prein-
cubation (either 1 lM or 10 lM) without TNF had no effect on
cellular adhesion. A concentration of 10 lM SPC was used in all
subsequent experiments. As SPC could be acting on BMDM or
SMC (or both cell types simultaneously) to produce its anti-
adhesive effect, either BMDM or SMC were preincubated with
10 lM SPC for 24 h before co-culture. When SMC were preincu-
bated with SPC and co-cultured with BMDM, SPC retained a signif-
icant inhibitory effect on TNF-induced adhesion (Fig. 1B). However,
BMDM preincubated with SPC for 24 h and co-cultured with SMC
did not alter BMDM adhesion compared to vehicle-treated BMDM(Fig. 1C). This demonstrates that the anti-adhesive action of SPC
occurs solely via effects on SMC.
3.2. SPC inhibits TNF-induced macrophage adhesion to SMC via S1P2
and lipid raft domains
We next wanted to determine the potential intracellular mech-
anisms of the anti-adhesive effect of SPC on vascular SMC. We
examined both the potential role of S1P receptors (receptor-
dependent) and the possible involvement of lipid rafts (potentially
receptor-independent). To determine whether SPC is exerting its
effect via S1P receptors, SMC were incubated with the S1P2 recep-
tor antagonist JTE-013 (Fig. 2A). Preincubation with JTE-013 signif-
icantly prevented the SPC-mediated inhibition of BMDM adhesion
to SMC indicate that SPC is acting, at least partly, via the S1P2
receptor. In further investigation of S1P receptor subtypes, the
experiment was repeated using the S1P1/S1P3 receptor antagonist
VPC-23019 (1 lM and 10 lM). Preincubation with VPC-23019
had no effect on the anti-adhesive action of SPC at either concen-
tration (results not shown). The involvement of lipid rafts was
assessed by incubating vascular SMC with methyl-b-cyclodextrin
which depletes cholesterol from the cell membrane. We have pre-
viously used this protocol in SMC to assess lipid raft involvement in
signalling mechanisms [28]. Vascular SMC were incubated with
SPC for 24 h and in the final hour of incubation 1 mM methyl-
b-cyclodextrin was added. Vascular SMC were subsequently co-
cultured with BMDM. While methyl-b-cyclodextrin incubation
did not alter levels of cellular adhesion in untreated cells and also
did not affect TNF-induced adhesion of BMDM to SMC, the anti-
adhesive effect of SPC was abolished (Fig. 2B). This indicates that
SPC is also acting at least partly via a lipid raft-dependent
mechanism.
3.3. SPC-induced changes to cell-cell adhesion occur via regulation of
NOS2 expression
Increases in cellular adhesion to SMC typically occur via the
adhesion proteins VCAM-1 and ICAM-1, therefore the effect of
SPC on the expression of these adhesion proteins was assessed.
SPC incubation for 24 h had no effect on basal levels of either
VCAM-1 or ICAM-1 expression in SMC (data not shown). TNF incu-
bation for up to 24 h produced a time-dependent increase in both
VCAM-1 (Fig. 3A) and ICAM-1 expression (Fig. 3B). When SMC
were incubated with TNF and SPC, there was no difference in the
increase in expression of either VCAM-1 or ICAM-1 compared to
TNF incubation alone. Thus, the anti-adhesive effect of SPC does
not occur via regulation of VCAM-1 and ICAM-1 expression.
We next investigated other potential signalling mechanisms
which may be involved in the SPC-induced decrease in BMDM
adhesion to vascular SMC. As nitric oxide synthase (NOS)2 expres-
sion (the proinflammatory NOS isoform) is upregulated by TNF in
many cell types and its product, NO, has been shown to influence
monocyte/macrophage interactions, we next determined if NO
had a role in the anti-adhesive effect of SPC [29]. SMC were prein-
cubated with either TNF or SPC or TNF + SPC in the presence of the
selective NOS2 inhibitor 1400W. These cells were subsequently co-
cultured with TNF-treated BMDM. Inhibition of NOS2 activity sig-
nificantly decreased the TNF-induced adhesion of SMC to BMDM
demonstrating a role for NOS2 in this process (Fig. 4A). The inhibi-
tory effect of 1400Wwas not additive with the anti-adhesive effect
of SPC indicating that SPC and 1400W are acting via the same
intracellular mechanisms (Fig. 4A). To examine if SPC can alter
the induction of NOS2 expression, SMC were incubated for 24 h
with either TNF or SPC or TNF + SPC and NOS2 expression deter-
mined. TNF induced a significant increase in NOS2 expression
(3-fold compared to control) (Fig. 4B). Incubation with SPC
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Fig. 1. A. Rat aortic SMC and rat BMDMwere incubated separately with either 1 lM or 10 lM SPC or vehicle for 24 h in presence (black bars) or absence (white bars) of 10 ng/
ml TNF. SMC were subsequently co-cultured with BMDM for 15 min and adherent BMDM counted (n = 8). Scale bar = 250 lm. B. Rat aortic SMC were incubated with 10 lM
SPC ± 10 ng/ml TNF for 24 h and BMDM were incubated separately with 10 ng/ml TNF only for 24 h (n = 12). Rat aortic SMC were subsequently co-cultured with BMDM for
15 min and adherent BMDM counted. C. Rat aortic SMC were incubated with 10 ng/ml TNF for 24 h and BMDMwere incubated separately with 10 lM SPC ± 10 ng/ml TNF for
24 h. Adherent BMDM were assessed as above (n = 6). Results are presented as fold change of adhesion relative to vehicle treatment. Data are expressed as mean ± sem, ⁄
denotes p < 0.05, NS denotes not significant.
46 C. Wirrig et al. / Biochemical Pharmacology 115 (2016) 43–50significantly decreased the TNF-induced NOS2 expression to con-
trol levels. In order to assess whether this SPC-dependent repres-
sion of NOS2 expression resulted in a functional change in NO
production, the nitrate concentration in conditioned medium from
SMC in Fig. 4B was measured. TNF incubation produced a signifi-
cant increase in nitrate production. This increase was prevented
by co-incubation with SPC (Fig. 4C). SPC therefore decreases NO
production by inhibiting NOS2 expression.
3.4. SPC prevents the TNF-induced inhibition of NOS2 expression via
S1P2
The signal transduction mechanisms for the SPC-mediated inhi-
bition of NOS2 expression were investigated. We determined
whether this effect was via the S1P2 receptor and/or via lipid raft
dependent signalling as shown in Fig. 2. Vascular SMC were incu-
bated as above with either TNF or SPC or TNF + SPC for 24 h inthe presence of the S1P2 antagonist JTE-013 (Fig. 5A). Following
JTE-013 incubation, SPC could not decrease NOS2 expression (com-
pared to Fig. 4B) indicating that this effect occurs via activation of
the S1P2 receptor. To examine whether lipid rafts are involved in
the repression of NOS2 expression, vascular SMC were incubated
as above with either TNF or SPC or TNF + SPC for 24 h with 1 mM
methyl-b-cyclodextrin (to disrupt lipid rafts) added for the final
hour (Fig. 5B). Under these conditions which prevent the anti-
adhesive effect of SPC (see Fig. 2B), the SPC-induced decrease in
NOS2 expression following TNF stimulation was unaffected. This
suggests that although SPC can inhibit NOS2 expression via S1P2
receptors, this does not require lipid raft domains. The SPC-
mediated decrease in BMDM adhesion to vascular SMCmust there-
fore involve 2 distinct mechanisms, one of which is independent of
S1P receptor activation and NOS2 but dependent on lipid rafts. In
order to further examine this lipid raft-dependent mechanism,
we examined the possibility that, although SPC did not alter
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C. Wirrig et al. / Biochemical Pharmacology 115 (2016) 43–50 47VCAM-1 and ICAM-1 expression to induce its anti-adhesive effect
on BMDM binding, it may regulate the localisation of these pro-
teins in membrane compartments (such as lipid rafts) which can
alter adhesion. Evidence indicates that cellular adhesion protein
localisation and cell–cell–adhesion can be regulated via lipid rafts
[30]. We investigated whether SPC is altering ICAM-1 and VCAM-1
membrane distribution in lipid rafts. This could occur via a direct
interaction of SPC with lipid rafts independent of membrane recep-
tors. Vascular SMC were incubated with SPC in the presence of TNF
for 24 h. The Triton X100-insoluble extracts containing lipid rafts
were separated by sucrose density gradient centrifugation.
Collected fractions were subjected to immunoblotting with
anti-ICAM-1 or anti-VCAM-1 antibodies. Caveolin-1 was used to
identify lipid raft fractions (predominantly located in fraction 4).
Following incubation with TNF for 24 h, both ICAM-1 and VCAM-
1 were distributed evenly across the membrane fractions including
the lipid raft fraction of SMC (Fig. 5C). This was similar to untreated
cells (not shown). The addition of SPC to cells for 24 h did not alterthis distribution. The anti-adhesive effect of SPC does not therefore
alter the membrane distribution of these cellular adhesion
molecules.4. Discussion
The interaction of monocytes/macrophages with vascular SMC
in vivo is a central component of the pathogenesis of cardiovascular
disease [10]. In this study, the effect of the naturally-occurring sph-
ingolipid SPC on macrophage adhesion to vascular SMC was inves-
tigated. SPC significantly decreased TNF-induced adhesion of
BMDM to vascular SMC in an in vitro co-culture model. This anti-
adhesive action of SPC occurred via an effect directly on SMC, but
not BMDM. The SPC-induced signal transduction is at least partly
receptor-dependent (via activation of the S1P2 receptor). The intra-
cellular mechanisms of this effect were not due to changes in the
expression or membrane distribution of the adhesion proteins
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48 C. Wirrig et al. / Biochemical Pharmacology 115 (2016) 43–50ICAM-1 and VCAM-1, however they were dependent on an inhibi-
tion of TNF-induced NOS2 expression via the S1P2 receptor. In addi-
tion, a distinct lipid raft-dependent mechanism is also involved
(independent of S1P receptors). This novel effect of SPC would be
expected to decrease localised vascular inflammation andmay have
important implications for cardiovascular disease.
The adhesion of monocytes/macrophages to vascular SMC can
be enhanced through the actions of cytokines such as TNF (as
demonstrated in this study), modified low density lipoproteins or
growth factors [8]. A major finding of this study is that SPC can
alter TNF-induced adhesion of macrophages to smooth muscle
cells. This is the first demonstration that SPC has a potentially ben-
eficial effect by inhibiting this specific cell–cell interaction. This
study required a relatively high concentration of 10 lM SPC to
observe significant effects and it remains to be determined
whether local concentrations can be achieved at this level. Wehave previously shown effects on vascular SMC such as SPC-
induced increases in intracellular calcium are maximal at these
concentrations [24]. Clearly, for such effects to be observed
in vivo, a localised source would be required. SPC is naturally pre-
sent circulating in blood and is elevated in serum, indicating it is
released from platelets and provides potential for significant loca-
lised concentration increases [18]. SPC is also a constituent compo-
nent of lipoproteins, predominantly found in high density
lipoprotein (HDL) [17]. It has been suggested that the beneficial
effects of sphingolipids in the cardiovascular system, including
SPC, may be mediated via sphingolipids bound to HDL [19]. Such
an action as that observed in the current study could occur
in vivo with HDL as a potential source and scaffold for SPC-
induced effects. Regardless of the potential in vivo source of SPC,
this study does indicate a mechanism which could be exploited
therapeutically as a drug target.
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Fig. 5. A. Rat aortic SMC were incubated with either 10 ng/ml TNF, 10 lM SPC or TNF + SPC for 24 h with 1 mM methyl-b-cyclodextrin (MbCD) added for the final hour of
incubation. Protein extracts were subjected to immunoblotting with anti-NOS2 antibody. Representative immunoblots are shown together with mean data (mean ± sem,
n = 4, ⁄ denotes p < 0.05). Results are normalised to vehicle treatment and presented as fold change of NOS2 expression. GAPDH served as a protein loading control. B. Rat
aortic SMC were incubated with either 10 ng/ml TNF, 10 lM SPC or TNF + SPC for 24 h in the presence of JTE-013 (1 lM added 60 min prior). Results are normalised to vehicle
treatment and presented as fold change of NOS2 expression. GAPDH served as a protein loading control. Data are expressed as mean ± sem, ⁄ denotes p < 0.05. C. Rat aortic
SMC were incubated with either 10 ng/ml TNF or TNF + 10 lM SPC for 24 h and membrane fractions prepared. Extracts were subjected to immunoblotting to reveal
expression of caveolin-1 (denotes lipid rafts, predominantly fraction 4), VCAM-1 and ICAM-1. Representative immunoblots are shown, n = 4.
C. Wirrig et al. / Biochemical Pharmacology 115 (2016) 43–50 49The anti-adhesive action of SPC was mediated entirely via vas-
cular SMC with macrophages having only a passive role. In addi-
tion, these effects were mediated, at least in part, via the S1P2
receptor on vascular SMC and required functional membrane lipid
rafts. Vascular SMC generally express S1P1–3 but the relative pro-
portion of each receptor subtype varies in different vascular beds
[15]. Although no high affinity receptor for SPC has been charac-
terised, in agreement with our findings suggesting involvement
of S1P2, a recent study has indicated that SPC can act via S1P2 to
induce a-smooth muscle actin expression in fibroblasts [31]. Addi-
tionally, receptor-independent effects as previously described may
also be involved as suggested by studies demonstrating receptor-
independent effects including the requirement for lipid rafts in
vascular smooth muscle cells [32,33]. We have similarly demon-
strated here that the anti-adhesive effect of SPC requires lipid raft
domains although their role is not yet clear. It is possible that SPC,
as a sphingolipid, is interacting directly with these cholesterol-rich
domains to induce signalling pathways. There is no evidence to
suggest that S1P2 receptors are resident exclusively in lipid raft
domains indicating that the SPC effects we observe here arepossibly due to 2 distinct mechanisms: a S1P receptor-dependent
pathway and a lipid raft-dependent/S1P receptor-independent
mechanism (although notably either blockade of S1P2 or disruption
of lipid rafts prevented the majority of SPC’s anti-adhesive effects).
Further knowledge of SPC pharmacology is required to fully delin-
eate the potentially complex interplay between these mechanisms.
Our investigation of the intracellular mechanisms involved in
the anti-adhesive effect of SPC surprisingly did not involve the well
characterised cellular adhesion proteins VCAM-1 and ICAM-1.
However, we focussed our study on NOS2, the NOS isoform closely
associated with inflammation. Cytokines such as TNF have previ-
ously been shown to induce expression of NOS2 in vascular SMC
[33]. In addition, SMC-monocyte interactions have been observed
to increase the expression of NOS2 [29]. We therefore examined
the potential role of NOS2 in macrophage adhesion to vascular
SMC. TNF incubation increased the expression of NOS2 in vascular
SMC. The importance of this increase in NOS2 expression to macro-
phage adhesion was demonstrated by a selective NOS2 inhibitor
1400W which inhibited TNF-induced BMDM adhesion. This is the
first evidence that the adhesion of macrophages to SMC requires
50 C. Wirrig et al. / Biochemical Pharmacology 115 (2016) 43–50the induction of NOS2 and is in contrast to constitutively expressed
NOS3 (endothelial NOS) which would decrease monocyte/
macrophage binding. The mechanisms involved in the NO-
induced increase in adhesion may be related to the high concentra-
tions of NO produced by NOS2 (compared to NOS3) resulting in the
formation of peroxynitrite via the actions of free radicals, leading
ultimately to nitrosative stress [34]. It has been demonstrated in
various vascular disease states (including atherosclerosis and
restenosis) that NOS2 expression is upregulated in vascular SMC
including those cells found in the neointima [35]. It is therefore
clear that in vivo NOS2 is present in a pro-inflammatory environ-
ment where monocyte/macrophage recruitment is actively occur-
ring and neointimal SMC are exposed. Having established the
importance of NOS2 expression in monocyte/macrophage adhe-
sion, we now reveal that SPC can repress the TNF-induced NOS2
expression in SMC, thereby decreasing adhesion. This occurred
via S1P2 receptor activation. A previous study has similarly demon-
strated that decreasing NOS2 expression can inhibit monocyte
adhesion to endothelial cells, although this study did not examine
sphingolipid effects [36]. The pathway uncovered by the current
study represents a previously unidentified sphingolipid-mediated
pathway which extends our knowledge of sphingolipid effects
relating to cardiovascular disease.
In conclusion, this study has uncovered a novel pathway which
can regulate macrophage adhesion to vascular SMC, a potentially
important interaction during the pathogenesis of vascular disease.
The naturally occurring sphingolipid SPC inhibits macrophage-SMC
adhesion via a mechanism which involves a repression of TNF-
induced NOS2 expression in SMC. Such an effect in vivo would
be of therapeutic benefit to limit the level inflammation associated
with cardiovascular disease and, subject to validation in disease
models, could be exploited as a new drug target.Disclosures
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